The Comparative Oncology Program of the University of California, Davis Cancer Center focuses on several specific aspects of cancer biology in animals. The first major theme, Tumor Biology, is the study of major Oncogenes, Tumor Suppressor genes. Cancer Stem Cells and Inflammation-Cancer. The second major theme. Genetically Defined Animal Models of Cancer, is the study of tumor development and progression employing transgenic and knockout animal models to elucidate basic mechanisms. The third major theme, Spontaneous Cancers in Large Animals, uses non-rodent animals to study tumor development and investigate novel diagnostics and therapeutics in a preclinical setting. This program brings a unique combination of skills and models to the preclinical setting. It provides the critical links between bench and bedside. The programmatic goals are: (1) to examine the signaling pathways of oncogenes and tumor suppressor genes and the role of inflammation and cancer stem cells in tumorigenesis using both in vitro systems and genetically defined animal models of cancer in vivo;(2) to characterize genetically induced tumorigenesis in animal models and development of novel animal models and experimental approaches;(3) to characterize spontaneous cancers in large animals and to perform preclinical evaluation of novel diagnostics and therapeutics;and (4) collaboration with other programs to facilitate translational research. The program has 29 members from ten different departments and three schools at UC Davis. It has 17 NCl funded projects for $2.6 million ADC (total peer-reviewed funding, $11.4 million ADC). The group has 524 publications for the last funding period;21% are inter-programmatic and 10% are intra-programmatic.
This program moves the discovery of new therapies for cancer by taking fundamental cancer discoveries and modeling them in mice. In addition, the program is unique in having 1300 patients (dogs and cats) that present with cancer to the veterinary school each year. By working together with colleagues treating human patients, the hope is to bring otherwise not available therapies to our veterinary patients, while speeding the discovery for new and effective therapies for our human patients.
|Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24|
|Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24|
|Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4|
|Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9|
|Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6|
|Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25|
|Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8|
|Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49|
|Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40|
|Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6|
Showing the most recent 10 out of 84 publications